Eli Lilly to buy AtaiBeckley in $2.8bn deal, could rise to $3.8bn
Eli Lilly will acquire AtaiBeckley for an upfront equity value of approximately $2.8 billion to gain access to therapies for treatment-resistant depression.
On Thursday, 16 July 2026, Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical firm based in New York. The transaction represents a move by the Indianapolis-based pharmaceutical company to expand its neuroscience and psychiatric medicine pipeline by gaining access to specialized experimental therapies.
Under the terms of the agreement, Eli Lilly will purchase all outstanding shares of AtaiBeckley common stock for a cash payment of $6.75 per share. This upfront cash consideration results in an equity value of approximately $2.8 billion. In addition to the base price, the deal includes a contingent value rights (CVR) structure that could add up to $2.50 per share to the total compensation, provided that specific clinical and regulatory milestones are reached. If all milestones are satisfied, the total potential consideration for the acquisition would reach approximately $3.8 billion.
Media additions
The CVR payments are tied to the progression of two specific programs: BPL-003 and VLS-01. The payout structure involves three tranches: $1.00 per share upon the initiation of a Phase 3 clinical trial for VLS-01 before the fourth anniversary of the deal's closing; $0.50 per share upon U.S. Regulatory approval and Drug Enforcement Administration (DEA) rescheduling of BPL-003 before the fifth anniversary; and $1.00 per share upon U.S. Regulatory approval and DEA rescheduling of VLS-01 before the seventh anniversary. The company noted that there is no assurance that any payments will be made concerning these rights.
The upfront cash offer represents a premium of approximately 26% over the closing price of AtaiBeckley stock on 15 July 2026, and roughly a 40% premium to the 30-day volume-weighted average trading price as of that date. The boards of directors for both companies have approved the transaction, and AtaiBeckley directors, officers, and Apeiron Investment Group, Ltd have signed support agreements to vote in favor of the merger. These shares account for roughly 15% of AtaiBeckley's outstanding common stock.
The primary focus of the acquisition is AtaiBeckley’s pipeline of rapid-acting neuroplastogens. The lead candidate, BPL-003, is a synthetic form of 5-MeO-DMT, or mebufotenin benzoate, administered via nasal spray. It is being developed to address treatment-resistant depression. The FDA has granted this program Breakthrough Therapy Designation, and Phase 3 activities have commenced. A Phase 2b study of BPL-003 suggested that patients experienced reductions in depressive symptoms following a single, roughly two-hour in-clinic session, with effects observed to last for months.
Carole Ho, executive vice president and president of Lilly Neuroscience, noted the difficulty faced by patients with this condition:
"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works."
Carole Ho, executive vice president and president, Lilly Neuroscience, via PR Newswire
Beyond BPL-003, the pipeline includes VLS-01, a DMT buccal film formulation currently in a Phase 2b trial for treatment-resistant depression, and EMP-01, an (R)-MDMA HCl derivative targeted at social anxiety disorder. The company is also researching non-hallucinogenic 5-HT2A agonists.
Srinivas Rao, co-founder and chief executive officer of AtaiBeckley, stated the company's objective regarding the biological basis of psychiatric conditions:
"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms."
Srinivas Rao, co-founder and chief executive officer, AtaiBeckley, via PR Newswire
The acquisition is expected to conclude in the third quarter of 2026. The deal remains subject to approval by AtaiBeckley stockholders, regulatory clearances, and other customary closing conditions. It is not subject to any financing requirements.
